<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791371</url>
  </required_header>
  <id_info>
    <org_study_id>20-2723</org_study_id>
    <secondary_id>R01DK124344</secondary_id>
    <nct_id>NCT04791371</nct_id>
  </id_info>
  <brief_title>Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes</brief_title>
  <acronym>REACH</acronym>
  <official_title>Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this two-site grant proposal is to determine the role of the decreased&#xD;
      insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development&#xD;
      of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In&#xD;
      addition, it is also our goal to determine whether exercise training attenuates insulin&#xD;
      resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle,&#xD;
      leading to improved cardiac function and exercise performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is our goal to determine whether exercise training attenuates insulin resistance and&#xD;
      restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved&#xD;
      cardiac function and exercise performance. Data from our two research teams suggest that the&#xD;
      cardiac and skeletal muscle microvascular dysfunction present in people with type 2 diabetes&#xD;
      contributes to limitations in cardiac and skeletal muscle function associated with impaired&#xD;
      functional exercise capacity (a major predictor of CV and all-cause mortality). Insulin&#xD;
      action is a potent predictor of the functional exercise capacity impairment in type 2&#xD;
      diabetes. The exact relationship between insulin action, cardiac and muscle dysfunction,&#xD;
      cardiac and skeletal muscle perfusion and decreased functional exercise capacity in type 2&#xD;
      diabetes remains unclear.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak oxygen consumption (VO2)</measure>
    <time_frame>Through study completion, approximately 4 months</time_frame>
    <description>Subjects' peak oxygen consumption will be tested on a stationary bike before and after 15 weeks of exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Through study completion, approximately 4 months</time_frame>
    <description>The investigators will evaluate the changes in insulin sensitivity utilizing a euglycemic insulin clamp</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 30-55 with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy overweight control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 30-55 with BMI 25-40 without type 2 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cardiovascular exercise</intervention_name>
    <description>15 weeks of cardiovascular exercise 3x/week for 50 minutes/session</description>
    <arm_group_label>Healthy overweight control</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sedentary (defined as less than 1 hour per week of physical activity)&#xD;
&#xD;
          -  BMI: 25-40&#xD;
&#xD;
          -  Men and women with and without type 2 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled hypertension: disease systolic blood pressure (SBP) &gt; 150, diastolic&#xD;
             blood pressure (DBP)&gt; 110&#xD;
&#xD;
          -  Obstructive pulmonary disease or asthma&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Physical impairment that would limit exercise ability&#xD;
&#xD;
          -  Subjects taking beta blockers, calcium channel blockers, insulin, or&#xD;
             Thiazolidinediones (TZD)&#xD;
&#xD;
          -  Current or past smoking within the last 1 years&#xD;
&#xD;
          -  Current tobacco use&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Control HbA1c &gt; 5.7, T2DM HbA1c &gt; 9&#xD;
&#xD;
          -  Pregnant, nursing or hormonal therapy (other than contraceptives)&#xD;
&#xD;
          -  Peri or post-menopausal women&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Hepatic or renal disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deirdre Rafferty, MS</last_name>
    <phone>720-848-6688</phone>
    <email>deirdre.rafferty@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Deirdre Rafferty, MS</last_name>
      <phone>720-848-6688</phone>
      <email>deirdre.rafferty@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Chapman, BS</last_name>
      <phone>720-848-6690</phone>
      <email>kristina.chapman@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Judy Regensteiner, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Reusch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lee Hartline, MEd</last_name>
      <phone>434-924-5247</phone>
      <email>lmh9d@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Jahn, RN</last_name>
      <phone>434-924-1134</phone>
      <email>las6e@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zhenqi Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

